Table 3.

Effect of compounds on Parkinson’s disease

Compound	Cell Culture	C. elegans	Drosophila	Mouse	Human
Metformin	Protective1–4	Protective5	Protective6	Protective1, 2, 4, 7, 8	Protective9, 10 Deleterious11
Resveratrol	Protective12–15	N/A	Deleterious16	Protective15, 17–23	N/A
Rapamycin	Protective24, 25	Protective26	Protective27	Protective24, 25, 28, 29	N/A
NAC	Protective30	N/A	N/A	Protective31, 32	Protective30
Curcumin	Protective33–36	N/A	Protective37	Protective38–45	N/A

^1.Lu M, et al. (2016) Int J Neuropsychopharmacol 19(9).

^2.Bayliss JA, et al. (2016) PloS one 11(7).

^3.Dulovic M, et al. (2014) Neurobiology of disease 63.

^4.Kang H, et al. (2017) Oncotarget 8(30).

^5.Saewanee N, et al. (2019) Neuroscience Research.

^6.Ng C-H, et al. (2012) J Neurosci 32(41).

^7.Adedeji HA, et al. (2014) Prog Neuropsychopharmacol Biol Psychiatry 48.

^8.Yan Q, et al. (2017) Mol Pharmacol 92(6).

^9.Wahlqvist ML, et al. (2012) Parkinsonism Relat Disord 18(6).

^10.Shi Q, et al. (2019) BMJ Open 9(7).

^11.Kuan Y-C, et al. (2017) Prog Neuropsychopharmacol Biol Psychiatry 79(Pt B).

^12.Alvira D, et al. (2007) Neuroscience 147(3).

^13.Wu Y, et al. (2011) Neuro-Signals 19(3).

^14.Ferretta A, et al. (2014) Biochimica et biophysica acta 1842(7).

^15.Wang ZH, et al. (2015) Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 74.

^16.Bagatini PB, et al. (2011) Invertebrate neuroscience : IN 11(1).

^17.Blanchet J, et al. (2008) Progress in neuro-psychopharmacology & biological psychiatry 32(5).

^18.Jin F, et al. (2008) European journal of pharmacology 600(1–3).

^19.Khan MM, et al. (2010) Brain research 1328.

^20.Gaballah HH, et al. (2016) Chemico-biological interactions 251.

^21.Zhang LF, et al. (2018) Food & function 9(12).

^22.Liu Q, et al. (2019) Behavioural brain research 367.

^23.Xia D, et al. (2019) Journal of cellular biochemistry 120(4).

^24.Malagelada C, et al. (2010) J Neurosci 30(3).

^25.Dehay B, et al. (2010) J Neurosci 30(37).

^26.Tyson T, et al. (2017) Sci Rep 7(1).

^27.Tain LS, et al. (2009) Nat Neurosci 12(9).

^28.Masini D, et al. (2018) Front Neurol 9.

^29.Crews L, et al. (2010) PLoS One 5(2).

^30.Monti DA, et al. (2016) PLoS One 11(6).

^31.Rahimmi A, et al. (2015) Brain Research Bulletin 113.

^32.Clark J, et al. (2010) PloS one 5(8).

^33.van der Merwe C, et al. (2017) Mol Neurobiol 54(4).

^34.Jayaraj RL, et al. (2013) J Mol Neurosci 51(3).

^35.Qualls Z, et al. (2014) Neurotox Res 25(1).

^36.Sang Q, et al. (2018) Cell Physiol Biochem 51(2).

^37.Nguyen TT, et al. (2018) Oxid Med Cell Longev 2018.

^38.Zbarsky V, et al. (2005) Free Radic Res 39(10).

^39.Du XX, et al. (2012) Neurosci Bull 28(3).

^40.Rajeswari A, et al. (2008) Inflammopharmacology 16(2).

^41.Chiu S, et al. (2013) J Complement Integr Med 10.

^42.Pan J, et al. (2012) Translational Neurodegeneration 1.

^43.Jayaraj RL, et al. (2014) Biomed Res Int 2014.

^44.Abbaoui A, et al. (2017) Neurosci Lett 660.

^45.Sharma N, et al. (2018) Inflammopharmacology 26(2).